In a welcome move, Harmony Biosciences saw its Relative Strength Rating improve from 63 to 74 on Tuesday.
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
History reveals that the best stocks often have an RS Rating of above 80 as they launch their biggest price moves. See if Harmony Biosciences can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Harmony Biosciences is building a consolidation with a 41.61 buy point. See if the stock can clear the breakout price in heavy volume.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 6% to 48%. Revenue rose from 16% to 20%.
The company holds the No. 14 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
